Lv1
90 积分 2024-01-23 加入
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
5天前
已完结
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
8天前
已完结
Current understanding and management of CAR T cell-associated toxicities
9个月前
已完结
Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia
9个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
1年前
已完结
Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care
1年前
已完结
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma
1年前
已完结
CD70 CXCR2-Modified CAR T-Cells Against Acute Myeloid Leukemia
1年前
已完结
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
1年前
已完结
皖公网安备34019202002308
